---
title: "Case Control Study: Determinants of Osteoporosis in GOLD II COPD Patients."
nct_id: NCT00725673
overall_status: COMPLETED
sponsor: Catharina Ziekenhuis Eindhoven
study_type: OBSERVATIONAL
primary_condition: Chronic Obstructive Pulmonary Disease
countries: Netherlands
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00725673.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00725673"
ct_last_update_post_date: 2009-11-10
last_seen_at: "2026-05-12T06:19:30.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Case Control Study: Determinants of Osteoporosis in GOLD II COPD Patients.

**Official Title:** Determination of Risk Factors for Developing Osteoporosis in COPD GOLD II Patients. A Case Control Study to Identify Possible Risk Factors for Developing Osteoporosis in COPD GOLD II Patients.

**NCT ID:** [NCT00725673](https://clinicaltrials.gov/study/NCT00725673)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 106
- **Lead Sponsor:** Catharina Ziekenhuis Eindhoven
- **Conditions:** Chronic Obstructive Pulmonary Disease, Osteoporosis
- **Start Date:** 2007-09
- **Completion Date:** 2009-06
- **CT.gov Last Update:** 2009-11-10

## Brief Summary

Patients with COPD have been found to have an increased risk of osteoporosis. The underlying mechanism is not clear yet. This case control study aims to identify risk factors for osteoporosis in GOLD II COPD patients. COPD GOLD II patients with osteoporosis (cases) will be matched by gender and age to COPD GOLD II patients without osteoporosis(controls).

Possible risk factors for osteoporosis are:

* BMI/VVMI (body composition)
* emphysema vs chronic bronchitis
* physical capacity
* Use of certain medication (eg corticosteroids, SSRI's)
* Nutritional status
* Infectious parameters Outpatients from the pulmonary ward of the Catharina Hospital Eindhoven with GOLD II COPD according to the ATS and GOLD-guidelines will be included in the study (after written informed consent).

A DEXA-scan will be made, if patients are osteoporotic or have a normal BMD they will be included in the study.

A HRCT will be made, a six minutes walking distance will be performed, blood will be drawn for lab. analysis, an X-ray of the vertebral collum will be made, impedance will be measured and hight and weight will be measuered. Also patients will fill in a questionaire.

By univariate and multivariate analysis the collected data will be analysed to determine possible risk factors for th development of osteoporosis in COPD GOLD II patients.

## Eligibility

- **Minimum age:** 40 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age \>= 40 years
* GOLD II COPD
* Written permission

Exclusion Criteria:

* Age \< 40 years
* No COPD or COPD GOLD I, III or IV
* no written permission
```

## Arms

- **1** — GOLD II COPD patients with osteoporosis
- **2** — GOLD II COPD patients with a normal bone mineral density

## Primary Outcomes

- **Risk factors for osteoporosis in GOLD II COPD patients** _(time frame: 1 year)_

## Locations (1)

- Catharina Hospital Eindhoven, Eindhoven, North Brabant, Netherlands

## Recent Field Changes (last 30 days)

- `status.completionDate` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.catharina hospital eindhoven|eindhoven|north brabant|netherlands` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00725673.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00725673*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*